Novel Therapeutic Uses of Alpha-1 Antitrypsin: A Window to the Future

Selected References (submitted by the presenters)

Type-1 diabetes and other immune-mediated diseases

• Grimstein C. Combination of alpha-1 antitrypsin and doxycycline suppresses collagen-induced arthritis. J Gene Med 2001; 12:35–44.
   Google Scholar
• Grimstein C. Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model. J Transl Med 2011; 9:21.
   PubMedGoogle Scholar
• Hashemi M, Naderi M, Rashidi H, Ghavami S. (2007) Impaired activity of serum alpha-1-antitrypsin in diabetes mellitus. Diabetes Res Clin Pract 75:246–248.
   PubMed Web of Science ®Google Scholar
• Hill AT, Campbell EJ, Bayley DL, Hill SL, Stockley RA. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med 1999; 160:1968–1975.
   PubMed Web of Science ®Google Scholar
• Huang H, Campbell SC, Nelius T, Alpha1-antitrypsin inhibits angiogenesis and tumor growth. Int J Cancer 2004; 112:1042–1048.
   PubMed Web of Science ®Google Scholar
• Koulmanda M, Bhasin M, Hoffman L, Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci USA 1008; 105:16242–16247.
   Google Scholar
• Lewis EC, Mizrahi M, Toledano M, alpha1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc Natl Acad Sci USA 2008; 105:16236–16241.
   PubMed Web of Science ®Google Scholar
• Lewis EC, Shapiro L, Bowers OJ, Dinarello CA. Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice. Proc Natl Acad Sci USA 2005; 102:12153–12158.
   PubMed Web of Science ®Google Scholar
• Lu Y. Therapeutic level of functional human alpha 1 antitrypsin (hAAT) secreted from murine muscle transduced by adeno-associated virus (rAAV1) vector. J Gene Med 2006; 8: 730–735.
   PubMed Web of Science ®Google Scholar
• Lu Y. Alpha1-antitrypsin gene therapy modulates cellular immunity and efficiently prevents type 1 diabetes in nonobese diabetic mice. Hum Gene Ther 2006; 17:625–634.
   PubMed Web of Science ®Google Scholar
• Lu Y. Human alpha 1-antitrypsin therapy induces fatal anaphylaxis in non-obese diabetic mice. Clin Exp Immunol 2008; 154: 15–21.
   PubMed Web of Science ®Google Scholar
• Ma H. Intradermal alpha1-antitrypsin therapy avoids fatal anaphylaxis, prevents type 1 diabetes and reverses hyperglycaemia in the NOD mouse model of the disease. Diabetologia 2010; 53:2198–2204.
   PubMed Web of Science ®Google Scholar
• Marcondes AM, Xiang L, Tabellini L, Bartenstein M, Kabacka J, Sale GE, Dinarello CA, Deeg HJ. Inhibition of IL-32 activation by a-1 anti-trypsin reduces alloreactivity and increases survival in an allogeneic murine marrow transplantation model. Blood 2011; 118:5031–5039.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Okabe Y, Setoyama H, Takayama K, Ohtsuka J, Funahashi H, Imaoka A, Okada Y, Umesaki Y. Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain. Gut 1998; 43:71–78.
   PubMed Web of Science ®Google Scholar
• Petrache I, Fijalkowska I, Zhen L, Medler TR, Brown E, Cruz P, Choe KH, Taraseviciene-Stewart L, Scerbavicius R, Shapiro L, Zhang B, Song S, Hicklin D, Voelkel NF, Flotte T, Tuder RM. A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. Am J Respir Crit Care Med 2006; 173:1222–1228.
   PubMed Web of Science ®Google Scholar
• Rivera-Nieves J, Bamias G, Vidrich A, Marini M, Pizarro TT, McDuffie MJ, Moskaluk CA, Cohn SM, Cominelli F. Emergence of perianal fistulizing disease in the SAMP1/YitFc mouse, a spontaneous model of chronic ileitis. Gastroenterology 2003; 124:972–982.
   PubMed Web of Science ®Google Scholar
• Sandler M, Gemperli BM, Hanekom C, Kuhn SH. Serum alpha 1-protease inhibitor in diabetes mellitus: reduced concentration and impaired activity. Diabetes Res Clin Pract. 1988; 5:249–255.
   PubMed Web of Science ®Google Scholar
• Shahaf G, Moser H, Ozeri E, Mizrahi M, Abecassis A, Lewis EC. alpha-1-antitrypsin gene delivery reduces inflammation, increases T-regulatory cell population size and prevents islet allograft rejection. Mol Med 2011; 17:1000–1011.
   PubMed Web of Science ®Google Scholar
• Song S. Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice. Gene Ther 2004; 11:181–186.
   PubMed Web of Science ®Google Scholar
• Toldo S, Seropian IM, Mezzaroma E, Van Tassell BW, Salloum FN, Lewis EC, Voelkel N, Dinarello CA, Abbate A. Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. J Mol Cell Cardiol 2011; 51:244–251.
   PubMed Web of Science ®Google Scholar
• Zhang SQ, Zhong XY, Chen GH, Lu WL, Zhang Q. The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats. J Pharm Pharmacol 2008; 60:99–105.
   PubMed Web of Science ®Google Scholar

Viral Diseases

• Bryan CL, Beard KS, Pott GB, Rahkola J, Gardner EM, Janoff EN, Shapiro L. HIV infection is associated with reduced serum alpha-1-antitrypsin concentrations. Clin Invest Med 2010; 33:384–389.
   Google Scholar
• Dhami R, Zay K, Gilks B, Porter S, Wright JL, Churg A. Pulmonary epithelial expression of human alpha1-antitrypsin in transgenic mice results in delivery of alpha1-antitrypsin protein to the interstitium. J Mol Med 1999; 77:377–385.
   PubMed Web of Science ®Google Scholar
• Forssmann WG, The YH, Stoll M, Adermann K, Albrecht U, Barlos K, Busmann A, Canales- Mayordomo A, Gimenez-Gallego G, Hirsch J, Jimenez-Barbero J, Meyer-Olson D, Munch J, Perez- Castells J, Standker L, Kirchhoff F, Schmidt RE. Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide. Sci Transl Med 2010; 2:63.
   Google Scholar
• Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 2007; 129:263–275.
   PubMed Web of Science ®Google Scholar
• Shapiro L, Pott GB, Ralston AH. Alpha-1-antitrypsin inhibits human immunodeficiency virus type-1. FASEB J 2001; 15:115–122.
   PubMed Web of Science ®Google Scholar

Non-alpha-1 lung disease

• Brand P, Schulte M, Wencker M, Herpich CH, Klein G, Hanna K, Meyer T. Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency. Eur Respir J 2009; 34:354–360.
   PubMed Web of Science ®Google Scholar
• Carp H, Miller F, Hoidal JR, Janoff A. Potential mechanism of emphysema: alpha 1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity. Proc Natl Acad Sci 1982; 79:2041–2045.
   PubMed Web of Science ®Google Scholar
• Griese M, Latzin P, Kappler M, Weckerle K, Heinzlmaier T, Bernhardt T, Hartl D. Alpha1-antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007; 29:240–250.
   PubMed Web of Science ®Google Scholar
• Hansen G, Schuster A, Zubrod C, Wahn V. Alpha 1-proteinase inhibitor abrogates proteolytic and secretagogue activity of cystic fibrosis sputum. Respiration 1995; 62:117–124.
   PubMed Web of Science ®Google Scholar
• Hubbard RC, Brantly ML, Sellers SE, Mitchell ME, Crystal RG. Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha 1-antitrypsin deficiency directly augmented with an aerosol of alpha 1-antitrypsin. Ann Intern Med. 1989; 111:206–212.
   PubMed Web of Science ®Google Scholar
• Janciauskiene SM, Bals R, Koczulla R, Vogelmeier C, Köhnlein T, Welte T. The discovery of α1-antitrypsin and its role in health and disease. Respir Med 2011; 105:1129–1139.
   PubMed Web of Science ®Google Scholar
• Kerem E, Bauer S, Strauss P, Jaffe N, Armoni S, Pugatsch T, Shoseyov D, Tov N. Safety/efficacy of inhaled human alpha-1 antitrypsin (AAT) in CF: a phase II clinical study. J Cyst Fibr 2009; 8:S25.
   Google Scholar
• Martin SL*, Downey D, Bilton D, Keogan MT, Edgar J, Elborn JS. Safety and efficacy of recombinant alpha1-antitrypsin therapy in cystic fibrosis. Ped Pulmonol 2006; 41:177–183.
   PubMed Web of Science ®Google Scholar
• McElvaney NG, Hubbard RC, Birrer P, Chernick MS, Caplan DB, Frank MM, Crystal RG. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 1991; 337:392–394.
   PubMed Web of Science ®Google Scholar
• Mogayzel PJ Jr, Flume PA. Update in cystic fibrosis. Am J Respir Crit Care Med 2010; 181:539–544.
   PubMed Web of Science ®Google Scholar
• Taggart C, Cervantes-Laurean D, Kim G, McElvaney NG, Wehr N, Moss J, Levine RL. Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity. J Biol Chem 2000; 275:258–265.
   Google Scholar
• Taggart C, Coakley RJ, Greally P, Canny G, O'Neill SJ, McElvaney NG. Increased elastase release by CF neutrophils is mediated by tumor necrosis factor-alpha and interleukin-8. Am J Physiol Lung Cell Mol Physiol 2000; 278:33–41.
   PubMed Web of Science ®Google Scholar
• Tawara I, Sun Y, Lewis EC, Toubai T, Evers R, Nieves E, Azam T, Dinarello CA, Reddy P. Alpha-1 antitrypsin monotherapy reduces graft-vesrsus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci USA 2012; 109:564–569.
   PubMed Web of Science ®Google Scholar
• Travis J. Structural evidence for methionine at the reactive site of human alpha-1- proteinase inhibitor. J Biol Chem 1978; 253:7142–7144.
   PubMed Web of Science ®Google Scholar
• Walsh DE, Greene CM, Carroll TP, Taggart CC, Gallagher PM, O'Neill SJ, McElvaney NG. Interleukin-8 up-regulation by neutrophil elastase is mediated by MyD88/IRAK/TRAF-6 in human bronchial epithelium. J Biol Chem 2001; 276:35494–35499.
   PubMed Web of Science ®Google Scholar